Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.46 |
| ▸ | GRM5 | P41594 | 11/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841532 | 0.85 | GRM1 (0.46) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL15615840 | 0.82 | PDK4 (0.46) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL13542726 | 0.81 | GRM1 (0.43) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL18293252 | 0.80 | PDK4 (0.48) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL10225837 | 0.80 | GRM5 (0.46) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL5078071 | 0.79 | PDK4 (0.43) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL212403 | 0.79 | PDK4 (0.46) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL27521647 | 0.78 | PDK4 (0.53) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL29233999 | 0.78 | PDK4 (0.46) | GRM1GRM5PDK4NAMPTESR2 | |
| SCHEMBL18068367 | 0.78 | PDK4 (0.46) | GRM1GRM5PDK4NAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-7449485-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1487811-B1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7030115-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2006-04-06 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | ABBVIE INC. | 2003-12-25 | — | — | US | disclosed |
| EP-1318978-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2002024636-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | GRM1 3908/4885GRM5 4564/4885PDK4 3537/4885 |
| US-20080146572-A1 | N-SULFONYLUREA APOPTOSIS PROMOTERS | BAX, BCL2, BAD | GRM1 3275/4885GRM5 2684/4885PDK4 1750/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | GRM1 4136/4885GRM5 4584/4885PDK4 3479/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | GRM1 3908/4885GRM5 4564/4885PDK4 3537/4885 |
| US-20060074085-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, BAD | GRM1 3275/4885GRM5 2684/4885PDK4 1750/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | GRM1 4652/4885GRM5 4474/4885PDK4 3345/4885 |
| US-20030236247-A1 | N-sulfonylurea apoptosis promoters | BAX, BCL2, AIFM1 | GRM1 2636/4885GRM5 3429/4885PDK4 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.